Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus

Diabetes Therapy

Volumn 8, Issue 2, 2017, Pages 275-291

  Evans, Marc ^a   Chubb, Barrie ^b   Gundgaard, Jens ^c  

^a LLANDOUGH HOSPITAL   (United Kingdom)

^b Novo Nordisk Ltd   (United Kingdom)

^c NOVO NORDISK A S   (Denmark)

Author keywords

Cost effective; Diabetes; Hypoglycaemia; ICER; Insulin analogue; Insulin degludec; QALY

Indexed keywords

INSULIN DEGLUDEC; INSULIN GLARGINE;

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 85016993505     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-017-0236-9     Document Type: Article

References (47)

1. Zhang P, Zhang X, Brown J, et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:293–301.
2. Hex N, Bartlett C, Wright D, Taylor M, Varley D. Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med. 2012;29:855–62.
3. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.
4. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–53.
5. National Institute for Health and Care Excellence (NICE). NICE Guideline 17. Type 1 diabetes in adults: diagnosis and management. 2015. http://www.nice.org.uk/guidance/ng17. Accessed 23 Dec 2016.
6. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–9.
7. NHS Health, Social Care Information Centre. Quality and outcomes framework for diabetes 2013–14. https://mqi.ic.nhs.uk/IndicatorDefaultView.aspx?ref=1.09.04.21. Accessed 23 Dec 2016.
8. Davies M, Gagliardino J, Gray L, Khunti K, Mohan V, Hughes R. Real-world factors affecting adherence to insulin therapy in patients with type 1 or type 2 diabetes mellitus: a systematic review. Diabet Med. 2013;30:512–24.
9. Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28:2673–9.
10. Heise T, Nosek L, Bottcher SG, Hastrup H, Haahr H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab. 2012;14:944–50.
11. Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet. 2014;53:787–800.
12. Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012;14:859–64.
13. Ratner R, Gough SC, Mathieu C, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab. 2013;15:175–84.
14. Vora J, Christensen T, Rana A, Bain SC. Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials. Diabetes Ther. 2014;5:435–46.
15. Evans M, McEwan P, Foos V. Insulin degludec early clinical experience: does the promise from the clinical trials translate into clinical practice-a case-based evaluation. J Med Econ. 2015;18:96–105.
16. Sassi F. Calculating QALYs, comparing QALY and DALY calculations. Health Policy Plan. 2006;21:402–8.
17. National Institute for Health and Clinical Excellence. Measuring effectiveness and cost-effectiveness: the QALY. 2010. http://www.nice.org.uk/newsroom/features/measuringeffectivenessandcosteffectivenesstheqaly.jsp. Accessed 23 Dec 2016.
18. Ericsson A, Pollock RF, Hunt B, Valentine WJ. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden. J Med Econ. 2013;16:1442–52.
19. Evans M, Wolden M, Gundgaard J, Chubb B, Christensen T. Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin—from the UK health care cost perspective. Diabetes Obes Metab. 2014;16:366–75.
20. Evans M, Wolden M, Gundgaard J, Chubb B, Christensen T. Cost-effectiveness of insulin degludec compared with insulin glargine in a basal-bolus regimen in patients with type 1 diabetes mellitus in the UK. J Med Econ. 2015;18:56–68.
21. The Forum for Injection Technique (FIT). Diabetes care in the UK: the first UK injection technique recommendations. 2nd Edition. 2011. http://www.fit4diabetes.com/files/2613/3102/3031/FIT_Recommendations_Document.pdf. Accessed 23 Dec 2016.
22. Allbright E, Desmond R, Bell D. Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy. Diabetes Care. 2004;27:632–3.
23. Garg SK, Gottlieb PA, Hisatomi ME, et al. Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine. Diabetes Res Clin Pract. 2004;66:49–56.
24. Dhatariya KK, Yeong J. Improved glycaemic control for patients on a twice daily dosing regimen of insulin glargine compared to those on a once daily dosing regimen. Poster presentation at European Association for the Study of Diabetes, Stockholm 2010. Diabetologia. 2010;53:S390.
25. UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007;50:1140–7.
26. Evans M, Khunti K, Mamdani M, et al. Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries. Health Qual Life Outcomes. 2013;11:90.
27. Haymarket Media Group. Monthly Index of Medical Specialities (MIMS). 2016. http://www.mims.co.uk/. Accessed 23 Dec 2016.
28. Hammer M, Lammert M, Mejias SM, Kern W, Frier BM. Costs of managing severe hypoglycaemia in three European countries. J Med Econ. 2009;12:281–90.
29. Chubb B, Tikkanen C. The cost of non-severe hypoglycaemia In Europe. Value Health. 2015;18:A611.
30. Currie CJ, Morgan CL, Poole CD, Sharplin P, Lammert M, McEwan P. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin. 2006;22:1523–34.
31. Evans M, Jensen HH, Bogelund M, Gundgaard J, Chubb B, Khunti K. Flexible insulin dosing improves health-related quality-of-life (HRQoL): a time trade-off survey. J Med Econ. 2013;16:1357–65.
32. Boye KS, Matza LS, Walter KN, Van Brunt K, Palsgrove AC, Tynan A. Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur J Health Econ. 2011;12:219–30.
33. European Commission. What you need to know about biosimilar medicinal products. A consensus information document. 2013. https://www.google.co.uk/webhp?sourceid=chrome-instant&ion=1&espv=2&ie=UTF-8#q=European+Commission+Consensus+Paper+%E2%80%9CWhat+you+need+to+know+about+Biosimilar+Medicinal+Products%E2%80%9D+Synopsis%3A+Provides+background+on+the+view+of+biosimiars+from+the+authorities%E2%80%99+perspective. Accessed 23 Dec 2016.
34. ®: summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000309/WC500047935.pdf. Accessed 23 Dec 2016.
35. ® EPAR. 2015. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000309/human_med_000955.jsp&mid=WC0b01ac058001d124. Accessed 23 Dec 2016.
36. Home PD, Bergenstal RM, Bolli GB, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (edition 4). Diabetes Care. 2015;38:2217–25.
37. Bolli GB, Riddle MC, Bergenstal RM, et al. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (edition 3). Diabetes Obes Metab. 2015;17:386–94.
38. Riddle MC, Bolli GB, Ziemen M, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (edition 1). Diabetes Care. 2014;37:2755–62.
39. Dornhorst A, Luddeke HJ, Sreenan S, et al. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort. Int J Clin Pract. 2007;61:523–8.
40. Frier BM, Jensen MM, Chubb BD. Hypoglycaemia in adults with insulin-treated diabetes in the UK: self-reported frequency and effects. Diabet Med. 2016;33(8):1125–32.
41. ®) 100units/mL solution for injection in pre-filled pen or cartridge and 200 units/mL solution for injection in pre-filled pen. 2016. https://www.scottishmedicines.org.uk/files/advice/insulin_degludec_Tresiba_2ndResub_FINAL_July_2016_Updated_30.07.16_for_website.pdf. Accessed 23 Dec 2016.
42. ®). http://www.awmsg.org/awmsgonline/app/appraisalinfo/3158. Accessed 23 Dec 2016.
43. Philis-Tsimikas A, Brod M, Niemeyer M, Ocampo Francisco AM, Rothman J. Insulin degludec once-daily in type 2 diabetes: simple or step-wise titration (begin: once simple use). Adv Ther. 2013;30:607–22.
44. Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin. 2004;20(Suppl 1):S5–26.
45. ® from other basal insulins: evidence from Swedish real-world data. Oral presentation #11. In EASD 52nd Annual Meeting, Munich, Germany; September 12–16, 2016, p. 12–16.
46. Lane W, Bailey TS, Gerety G, et al. SWITCH 1: reduced hypoglycemia with insulin degludec (IDeg) versus insulin glargine (IGlar), both U100, in patients with T1D at high risk of hypoglycemia: a randomized, double-blind, cross-over trial. 87-LB. Presented at the ADA 76th Annual Scientific Sessions, New Orleans, LA, USA; June 10–14, 2016, p. 10–14.
47. Wysham C, Bhargava A, Chaykin L, et al. SWITCH 2: reduced hypoglycemia with insulin degludec (IDeg) versus insulin glargine (IGlar), both U100, in patients with T2D at high risk of hypoglycemia: a randomized, double-blind, crossover trial. 90-LB. Presented at the ADA 76th Annual Scientific Sessions, New Orleans, LA, USA; June 10–14, 2016, p. 10–14.